Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016
Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014
“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015
Real-life study on the aPpropriaTeness of treatment in moderate COPD patients (OPTIMO) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
LATE-BREAKING ABSTRACT: Treating the most diseased segments in patients with severe emphysema: 6 month results from the STEP-UP randomized controlled trial (RCT) Source: International Congress 2015 – Advances in therapeutic bronchoscopy Year: 2015
Patients’ adherence to chronic treatment in lung diseases: Preliminary data from a randomized controlled trial Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016
Roflumilast for stable COPD: Meta-analysis of randomized controlled trials Source: International Congress 2014 – Clinical presentations Year: 2014
LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial Source: International Congress 2016 – Asthma management Year: 2016
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Efficacy of the Plasma Cluster® device in mild to moderate asthmatic children: A randomized, double-blind, placebo-controlled, proof-of-concept trial Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
An auto-titrating intelligent oxygen therapy (iO2T) system in COPD patients: A randomised cross-over trial Source: International Congress 2015 – Tele-rehabilitation in chronic lung diseases Year: 2015
LATE-BREAKING ABSTRACT: COPD-associated severe pulmonary hypertension (COPDPH): results of a 16-weeks prospective multicenter, double-blind, placebo-controlled randomized clinical trial (RCT) [SPHERIC-1 (http://clinicaltrials.gov/ct2/show/NCT01441934)] investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013
Comprehensive care programme for patients with chronic obstructive pulmonary disease (COPD) --- A randomized controlled trial (RCT) Source: International Congress 2015 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2015